Yang Gon Jin, Chairman of the Board
Mr. Jin joined the Board in 2020. He is the Co-Chief Executive Officer of HLB, Elevar’s parent company, and leads HLB Group as Chairman, bringing seasoned leadership and keen insights gained from a broad management background. He is committed to alleviating human disease and suffering by finding new treatments for patients with cancer and other illnesses throughout the world.
Sang Woo Nam, Board Member
Mr. Nam has worked for more than 30 years at major Korean conglomerates, managing a wide range of areas including finance, sales and administration. He is currently the Co-Chief Executive Officer of HLB Life Science, an affiliate of the HLB Group, and serves as Vice Chairman of the HLB Group.
Yoon Ki Baek, Board Member
Mr. Baek is an expert in finance and accounting, with over 30 years of experience overseeing these areas at major Korean conglomerates. He has served as the Chief Financial Officer of HLB and is currently the Co-Chief Executive Officer of HLB.
Dong-Gun Kim, J.D., Board Member
Mr. Dong Gun Kim joined the Board in 2020. He currently serves as Chief Executive Officer of Immunomic Therapeutics and previously as Chief Strategy Officer of Elevar and Chief Executive Officer of HLB. Prior to joining Elevar/HLB, Mr. Kim spent more than 30 years as a specialist in M&A, corporate finance and investment management at leading corporations and professional firms (law, investment banking and private equity) both in the U.S. and Korea. Mr. Kim has an A.B. in Physics from Harvard College and a J.D. from Harvard Law School.
Yong-Hae Han, PhD, Board Member
Dr. Han joined the Board in April 2022. He is the Co-Chief Executive Officer of HLB Life Science and leads all new drug development activities. Yong-Hae has played major roles in multiple R&D organizations in the United States and Korea.
Saeho Chong, PhD, Board Member
Dr. Chong was appointed to the role of Chief Executive Officer in March 2022 and is a member of the Executive Team. Saeho brings more than 25 years of senior management experience, including more than a decade of strategic development in the pharmaceutical industry.
